Service de chirurgie orthopédique pédiatrique, CHU Amiens-Picardie, Amiens, France; Laboratoire MP3CV, centre de recherche universitaire en santé, CHU Amiens-Picardie, université Picardie Jules-Verne, Amiens, France.
Service de chirurgie orthopédique pédiatrique, CHU Amiens-Picardie, Amiens, France; Laboratoire MP3CV, centre de recherche universitaire en santé, CHU Amiens-Picardie, université Picardie Jules-Verne, Amiens, France.
Orthop Traumatol Surg Res. 2024 May;110(3):103578. doi: 10.1016/j.otsr.2023.103578. Epub 2023 Feb 6.
Spasticity is a common motor disorder in children with cerebral palsy (CP). Upper limb CP impairment has a significant negative impact on daily activities. Botulinum toxin (BTX-A) injections are widely used to reduce spasticity, but their effectiveness is not well-defined. We performed a systematic review of literature to answer questions about the effectiveness of BTX-A injections in the upper limb in children with CP.
A systematic review of literature was conducted according to PRISMA guidelines. Eligible studies were randomized controlled trials with a high level of evidence on BTX-A upper limb injections in children. The outcomes analyzed included the study population, spasticity, quality of movement, activity limitations, quality of life, pain, appearance and side effects.
A total of 24 studies were included. The number of patients included was 1358 with a mean age between 3 and 11years. Improvement after BTX-A injection compared to the control group was observed for spasticity (n=10/19 studies), bimanual activities (Assisting Hand Assessment) (n=3/7), activity limitations (n=6/11), pain (n=2/2) and appearance (n=2/2). No study found an improvement in quality of life. Side effects were described in 16 studies and were moderate in all cases.
This review of literature showed that BTX-A injections can improve spasticity and particularly activity limitations when reasonable objectives are established.
IV, systematic review.
痉挛是脑瘫(CP)儿童常见的运动障碍。上肢 CP 损伤对日常活动有重大负面影响。肉毒毒素(BTX-A)注射被广泛用于减少痉挛,但它们的疗效尚未明确。我们对文献进行了系统回顾,以回答关于 BTX-A 注射在上肢脑瘫儿童中的有效性的问题。
根据 PRISMA 指南进行系统文献回顾。符合条件的研究为 BTX-A 上肢注射具有高级别证据的随机对照试验。分析的结果包括研究人群、痉挛、运动质量、活动受限、生活质量、疼痛、外观和副作用。
共纳入 24 项研究。患者人数为 1358 人,平均年龄为 3 至 11 岁。与对照组相比,BTX-A 注射后的改善情况如下:痉挛(n=10/19 项研究)、双手活动(辅助手评估)(n=3/7)、活动受限(n=6/11)、疼痛(n=2/2)和外观(n=2/2)。没有研究发现生活质量有所改善。16 项研究描述了副作用,所有情况下均为中度。
这项文献综述表明,BTX-A 注射可以改善痉挛,特别是在合理设定目标时,还可以改善活动受限。
IV,系统综述。